Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R



TSX:CXR.R - Post by User

Comment by GoldBug024on Jul 19, 2016 12:39pm
188 Views
Post# 25065544

RE:RE:Concordia’s Photodynamic Therapy Laser Receives Premarket Ap

RE:RE:Concordia’s Photodynamic Therapy Laser Receives Premarket ApSounds like an innovation to me. Innovate is to make changes to something established, especially by introducing new methods, ideas or products. Wish you were innovative Lattice but it's the same old song and dance LOLLL csn we put a new switch on you to turn you off?
LatticeInExile wrote: Hey Baggie, QLT Photherapeutics did it first with photofrin in the 1990's and Axcan Scandipharm got approval in 2003  (via fda access data).   You must be either fabulously rich, hate your money, or lost your mind to believe that Concordia tweeks to a laser is innovative.  What a joke. 

wordless wrote:
  • Concordia’s Photodynamic Therapy Laser Receives Premarket Approval
OAKVILLE, Ontario, July 19, 2016 — Concordia International Corp. said that the U.S. Food and Drug Administration has approved the Company's premarket approval application for its Photofrin 630 PDT (photodynamic therapy) Laser. 

PDT with Photofrin is a light-based cancer treatment that combines the photosensitizing drug Photofrin (porfimer sodium) with a specific wavelength of laser light to attack cancer cells. 

Concordia said the newly approved laser — designed for use with Photofrin to treat esophageal cancer, Barrett's Esophagus and non-small cell lung cancer — has been re-engineered with new controls and peripheral systems, while maintaining the same specifications with minimal changes to the treatment procedures. 

The Company is also evaluating Photofrin as a potential treatment for cholangiocarcinoma, or bile duct cancer, which is a rare disease affecting approximately 2,000 to 3,000 patients annually in the U.S.
 




<< Previous
Bullboard Posts
Next >>